Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

55 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study.
Lambertini M, Ferreira AR, Di Meglio A, Poggio F, Puglisi F, Sottotetti F, Montemurro F, Poletto E, Bernardo A, Risi E, Dellepiane C, Sini V, Minuti G, Grasso D, Fancelli S, Del Mastro L. Lambertini M, et al. Among authors: risi e. Clin Breast Cancer. 2017 Dec;17(8):601-610.e2. doi: 10.1016/j.clbc.2017.04.002. Epub 2017 Apr 11. Clin Breast Cancer. 2017. PMID: 28479052
Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study.
Lambertini M, Ferreira AR, Poggio F, Puglisi F, Bernardo A, Montemurro F, Poletto E, Pozzi E, Rossi V, Risi E, Lai A, Zanardi E, Sini V, Ziliani S, Minuti G, Mura S, Grasso D, Fontana A, Del Mastro L. Lambertini M, et al. Among authors: risi e. Oncologist. 2015 Aug;20(8):880-9. doi: 10.1634/theoncologist.2015-0020. Epub 2015 Jun 22. Oncologist. 2015. PMID: 26099741 Free PMC article.
Treatment of Metastatic Colorectal Cancer Patients ≥75 Years Old in Clinical Practice: A Multicenter Analysis.
Grande R, Natoli C, Ciancola F, Gemma D, Pellegrino A, Pavese I, Garufi C, Di Lauro L, Corsi D, Signorelli D, Sperduti I, Cortese G, Risi E, Morano F, Sergi D, Signorelli C, Ruggeri EM, Zampa G, Russano M, Gamucci T. Grande R, et al. Among authors: risi e. PLoS One. 2016 Jul 21;11(7):e0157751. doi: 10.1371/journal.pone.0157751. eCollection 2016. PLoS One. 2016. PMID: 27442239 Free PMC article.
Serum Metabolomic Profiles Identify ER-Positive Early Breast Cancer Patients at Increased Risk of Disease Recurrence in a Multicenter Population.
Hart CD, Vignoli A, Tenori L, Uy GL, Van To T, Adebamowo C, Hossain SM, Biganzoli L, Risi E, Love RR, Luchinat C, Di Leo A. Hart CD, et al. Among authors: risi e. Clin Cancer Res. 2017 Mar 15;23(6):1422-1431. doi: 10.1158/1078-0432.CCR-16-1153. Epub 2017 Jan 12. Clin Cancer Res. 2017. PMID: 28082280 Free PMC article.
A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients.
Risi E, Grilli A, Migliaccio I, Biagioni C, McCartney A, Guarducci C, Bonechi M, Benelli M, Vitale S, Biganzoli L, Bicciato S, Di Leo A, Malorni L. Risi E, et al. Breast Cancer Res Treat. 2018 Jul;170(2):329-341. doi: 10.1007/s10549-018-4766-2. Epub 2018 Mar 22. Breast Cancer Res Treat. 2018. PMID: 29564743
Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial.
Malorni L, Curigliano G, Minisini AM, Cinieri S, Tondini CA, D'Hollander K, Arpino G, Bernardo A, Martignetti A, Criscitiello C, Puglisi F, Pestrin M, Sanna G, Moretti E, Risi E, Biagioni C, McCartney A, Boni L, Buyse M, Migliaccio I, Biganzoli L, Di Leo A. Malorni L, et al. Among authors: risi e. Ann Oncol. 2018 Aug 1;29(8):1748-1754. doi: 10.1093/annonc/mdy214. Ann Oncol. 2018. PMID: 29893790 Free PMC article. Clinical Trial.
Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial.
Rossi L, Biagioni C, McCartney A, Migliaccio I, Curigliano G, Sanna G, Moretti E, Minisini AM, Cinieri S, Tondini C, Arpino G, Bernardo A, Martignetti A, Risi E, Pestrin M, Boni L, Benelli M, Biganzoli L, Di Leo A, Malorni L. Rossi L, et al. Among authors: risi e. Breast Cancer Res. 2019 May 29;21(1):71. doi: 10.1186/s13058-019-1149-5. Breast Cancer Res. 2019. PMID: 31142370 Free PMC article.
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting.
Pizzuti L, Krasniqi E, Barchiesi G, Della Giulia M, Izzo F, Sanguineti G, Marchetti P, Mazzotta M, Giusti R, Botticelli A, Gamucci T, Natoli C, Grassadonia A, Tinari N, Iezzi L, Tomao S, Tomao F, Tonini G, Santini D, Astone A, Michelotti A, De Angelis C, Mentuccia L, Vaccaro A, Magnolfi E, Gelibter A, Magri V, Cortesi E, D'Onofrio L, Cassano A, Rossi E, Cazzaniga M, Moscetti L, Omarini C, Piacentini F, Fabbri MA, Scinto AF, Corsi D, Carbognin L, Bria E, La Verde N, Samaritani R, Garufi C, Barni S, Mirabelli R, Sarmiento R, Veltri EM, D'Auria G, Paris I, Giotta F, Lorusso V, Cardillo F, Landucci E, Mauri M, Ficorella C, Roselli M, Adamo V, Ricciardi GRR, Russo A, Berardi R, Pistelli M, Fiorio E, Cannita K, Sini V, D'Ostilio N, Foglietta J, Greco F, Zamagni C, Garrone O, Di Cocco B, Baldini E, Livi L, Desideri I, Meattini I, Sarobba G, Del Medico P, De Tursi M, Generali D, De Maria R, Risi E, Ciliberto G, Sperduti I, Villa A, Barba M, Di Leo A, Vici P. Pizzuti L, et al. Among authors: risi e. Int J Cancer. 2020 Apr 1;146(7):1917-1929. doi: 10.1002/ijc.32583. Epub 2019 Aug 7. Int J Cancer. 2020. PMID: 31330065 Free PMC article.
55 results